Roswell Park's Phase 1 Trial Results For Triple-Negative Breast Cancer, With 66% Achieving Complete Or Near-Complete Remission And No Immune-Related Adverse Events; Findings Published In Journal For ImmunoTherapy Of Cancer
Roswell Park's Phase 1 Trial Results For Triple-Negative Breast Cancer, With 66% Achieving Complete Or Near-Complete Remission And No Immune-Related Adverse Events; Findings Published In Journal For ImmunoTherapy Of Cancer
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.